PFENYSEPharmaceutical PreparationsFiscal year ends December 31
PFIZER INC
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026
$29.44−0.14 (-0.47%)
Close on Oct 19, 2026
- Market cap
- $167.78B
- P/E (TTM)
- 38.7
- Dividend yield
- 5.84%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
74.3%−5.3 pts over 5 years
Net margin
12.4%−9.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -1.6% | -14.8% | +8.5% | +2.5% | |
| Gross profit | +1.6% | -11.4% | +7.0% | +1.7% | |
| Net income | -3.2% | -37.2% | -3.2% | +1.1% | |
| EPS, diluted | -3.5% | -37.1% | -3.6% | +2.1% | |
| Free cash flow | -7.7% | -29.6% | -5.7% | -3.7% | |
| Dividend per share | +1.8% | +2.2% | +2.4% | +4.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 11.6% | 14.5% | 8.9% | |
| Return on assets | 4.3% | 5.7% | 3.7% | |
| Current ratio | 1.25 | 1.35 | 1.16 | |
| Debt to equity | 0.71 | 0.63 | 0.75 | |
| Inventory turnover | 1.7× | 1.1× | 1.5× | |
| Capex to revenue | 3.5% | 5.3% | 4.2% | |
| Diluted shares | 6.16B | 5.63B | 5.71B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Pfizer generated $95.00B from operations and spent $17.39B on capital expenditure, dividends and share buybacks. 89% of that went back into the business.
Generated
$95.00B
Used
$17.39B
Capital expenditure$15.39B89%Dividends$00%Share buybacks$2.00B11%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin12.4%
×Asset turnover0.30×
×Equity multiplier2.41×
=Return on equity, FY20258.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 12.4% | 0.30× | 2.41× | 8.9% |
| FY2024 | 12.6% | 0.29× | 2.48× | 9.1% |
| FY2023 | 3.6% | 0.28× | 2.29× | 2.3% |
| FY2022 | 31.0% | 0.53× | 2.19× | 36.3% |
| FY2021 | 27.0% | 0.48× | 2.39× | 31.3% |
| FY2020 | 22.0% | 0.26× | 2.55× | 14.5% |
| FY2019 | 39.2% | 0.25× | 2.58× | 25.3% |
| FY2018 | 27.3% | 0.25× | 2.46× | 16.6% |
| FY2017 | 40.6% | 0.31× | 2.62× | 32.6% |
| FY2016 | 13.7% | 0.31× | 2.73× | 11.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$7.77B
- Cash generatingOperating cash flow above zero$11.70B
- Return on assets improvedROA up on the prior year3.5% → 3.6%
- Earnings backed by cashOperating cash flow above net income$11.70B vs $7.77B
- Less leverageLong-term debt to assets fell26.9% → 29.6%
- Better liquidityCurrent ratio rose1.17 → 1.16
- No dilutionShare count did not rise5.70B → 5.71B
- Gross margin improvedGross margin up on the prior year71.94% → 74.33%
- More efficientAsset turnover rose0.28 → 0.29